Treatment of Refractory Adrenocortical Carcinoma with Thalidomide: Analysis of 27 Patients from the European Network for the Study of Adrenal Tumours Registry

Abstract

Objective Adrenocortical carcinoma (ACC) is a rare malignancy with a dismal prognosis. In advanced stages, tumour control by mitotane and cytotoxic chemotherapy is often temporary and salvage treatments are warranted.

Methods Retrospective cohort study of participants in the prospective European Networks for the Study of Adrenal Tumours (ENSAT) registry. Main outcome measures were best response during treatment, progression-free survival (PFS), both measured according to RECIST 1.1 by two blinded radiologists, and overall survival (OS).

Results Twenty-seven patients (13 males; median age 44.1 years) progressing after mitotane and a median of 4 further systemic treatments were included. Thalidomide was administered as tolerated with a starting dose of 50 mg and target dose of 200 mg /d. The median interval between treatment initiation and first imaging was 10.5 (4.4-17.5) weeks. The best response to treatment was stable disease (SD, n=2) and progressive disease (n=25), with a median PFS of 11.2 weeks and a median OS of 36.4 weeks. The first patient with SD discontinued treatment due to mild epistaxis and diarrhea after 22.3 weeks. The second patient had SD at the second treatment evaluation after 25.2 weeks and continued thalidomide but then had clinical progression and deceased after 54.3 weeks. In general, thalidomide induced only mild or moderate adverse effects (mainly fatigue and gastrointestinal complaints).

Conclusion Thalidomide was overall well tolerated but resulted in disease control in only 2/27 (7.4%) patients. In the absence of predictive response markers, thalidomide should only be considered in exceptional cases as a salvage therapy in ACC.

Key words

adrenal - adverse events - cancer - efficacy - follow-up - outcome - progression - side-effects - staging - toxicity - treatment

^* M.K. and T.D. contributed equally to this work

• References

• 1 Bilimoria KY, Shen WT, Elaraj D. et al. Adrenocortical carcinoma in the United States: Treatment utilization and prognostic factors. Cancer 2008; 113: 3130-3136 doi:10.1002/cncr.23886
• 2 Golden SH, Robinson KA, Saldanha I. et al. Clinical review: Prevalence and incidence of endocrine and metabolic disorders in the United States: A comprehensive review. J Clin Endocrinol Metab 2009; 94: 1853-1878 doi:94/6/1853 [pii] 10.1210/jc.2008-2291
• 3 Fassnacht M, Kroiss M, Allolio B. Update in adrenocortical carcinoma. J Clin Endocrinol Metab 2013; 98: 4551-4564 doi:10.1210/jc.2013-3020
• 4 Else T, Kim AC, Sabolch A. et al. Adrenocortical carcinoma. Endocrine reviews 2014; 35: 282-326 doi:10.1210/er.2013-1029
• 5 Schteingart DE, Doherty GM, Gauger PG. et al. Management of patients with adrenal cancer: Recommendations of an international consensus conference. Endocr Relat Cancer 2005; 12: 667-680
• 6 Jurowich C, Fassnacht M, Kroiss M. et al. Is there a role for laparoscopic adrenalectomy in patients with suspected adrenocortical carcinoma? A critical appraisal of the literature. Hormone and metabolic research=Hormon- und Stoffwechselforschung=Hormones et metabolisme 2013; 45: 130-136 doi:10.1055/s-0032-1331743
• 7 Fassnacht M, Dekkers O, Else T et al. European Society of Endocrinology Clinical Practice Guidelines on the Management of Adrenocortical Carcinoma in Adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 2018. in press
• 8 Grubbs EG, Callender GG, Xing Y. et al. Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane. Ann Surg Oncol 2010; 17: 263-270 doi:10.1245/s10434-009-0716-x
• 9 Datrice NM, Langan RC, Ripley RT. et al. Operative management for recurrent and metastatic adrenocortical carcinoma. J Surg Oncol 2012; 105: 709-713. doi:10.1002/jso.23015
• 10 Erdogan I, Deutschbein T, Jurowich C. et al. The role of surgery in the management of recurrent adrenocortical carcinoma. J Clin Endocrinol Metab 2013; 98: 181-191 doi:10.1210/jc.2012-2559
• 11 Baur J, Buntemeyer TO, Megerle F. et al. Outcome after resection of Adrenocortical Carcinoma liver metastases: A retrospective study. BMC Cancer 2017; 17: 522. doi:10.1186/s12885-017-3506-z
• 12 Luton JP, Cerdas S, Billaud L. et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 1990; 322: 1195-1201
• 13 Haak HR, Hermans J, van de Velde CJ. et al. Optimal treatment of adrenocortical carcinoma with mitotane: Results in a consecutive series of 96 patients. Br J Cancer 1994; 69: 947-951
• 14 Baudin E, Pellegriti G, Bonnay M. et al. Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 2001; 92: 1385-1392
• 15 Terzolo M, Angeli A, Fassnacht M. et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 2007; 356: 2372-2380
• 16 Hermsen IG, Fassnacht M, Terzolo M. et al. Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: Results of a retrospective ENS@T multicenter study. J Clin Endocrinol Metab 2011; 96: 1844-1851 doi:jc.2010-2676 [pii] DOI 10.1210/jc.2010-2676
• 17 Berruti A, Grisanti S, Pulzer A. et al. Long-term outcomes of adjuvant mitotane therapy in patients with radically resected adrenocortical carcinoma. J Clin Endocrinol Metab 2017; 102: 1358-1365. doi:10.1210/jc.2016-2894
• 18 Megerle F, Herrmann W, Schloetelburg W. et al. Mitotane monotherapy in patients with advanced adrenocortical carcinoma. J Clin Endocrinol Metab 2018; 103: 1686-1695 doi:10.1210/jc.2017-02591
• 19 Fassnacht M, Terzolo M, Allolio B. et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 2012; 366: 2189-2197 doi:10.1056/NEJMoa1200966
• 20 Sperone P, Ferrero A, Daffara F. et al. Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: A multicenter phase II study. Endocr Relat Cancer 2010; 17: 445-453
• 21 Henning JEK, Deutschbein T, Altieri B. et al. Gemcitabine-based chemotherapy in adrenocortical carcinoma: A multicenter study of efficacy and predictive factors. J Clin Endocrinol Metab 2017; 102: 4323-4332 doi:10.1210/jc.2017-01624
• 22 Khan TS, Imam H, Juhlin C. et al. Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: Long-term survival in its adjuvant use. Ann Oncol 2000; 11: 1281-1287
• 23 Quinkler M, Hahner S, Wortmann S. et al. Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. J Clin Endocrinol Metab 2008; 93: 2057-2062
• 24 Wortmann S, Quinkler M, Ritter C. et al. Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. Eur J Endocrinol 2010; 162: 349-356 doi:EJE-09-0804 [pii] 10.1530/EJE-09-0804
• 25 Berruti A, Sperone P, Ferrero A. et al. Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma. Eur J Endocrinol 2012; 166: 451-458 doi:10.1530/EJE-11-0918
• 26 Kroiss M, Quinkler M, Johanssen S. et al. Sunitinib in refractory adrenocortical carcinoma: A phase II, single-arm, open-label trial. J Clin Endocrinol Metab 2012; 97: 3495-3503 doi:jc.2012-1419 [pii] DOI 10.1210/jc.2012-1419
• 27 Fraenkel M, Gueorguiev M, Barak D. et al. Everolimus therapy for progressive adrenocortical cancer. Endocrine 2013; 44: 187-192. doi:10.1007/s12020-013-9878-1
• 28 Fassnacht M, Berruti A, Baudin E. et al. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: A double-blind, randomised, phase 3 study. The Lancet Oncology 2015; 16: 426-435 doi:10.1016/S1470-2045(15)70081-1
• 29 Megerle F, Kroiss MHahner et al. Advanced adrenocortical carcinoma – what to do when first-line therapy fails? Experimental and Clinical Endocrinology and Diabetes 2018 revision submitted
• 30 Melchert M, List A. The thalidomide saga. The International Journal of Biochemistry & Cell biology 2007; 39: 1489-1499. doi:10.1016/j.biocel.2007.01.022
• 31 Kumar N, Sharma U, Singh C. et al. Thalidomide: chemistry, therapeutic potential and oxidative stress induced teratogenicity. Current topics in medicinal chemistry 2012; 12: 1436-1455
• 32 Licht JD, Shortt J, Johnstone R. From anecdote to targeted therapy: The curious case of thalidomide in multiple myeloma. Cancer cell 2014; 25: 9-11 doi:10.1016/j.ccr.2013.12.019
• 33 Shortt J, Hsu AK, Johnstone RW. Thalidomide-analogue biology: Immunological, molecular and epigenetic targets in cancer therapy. Oncogene 2013; 32: 4191-4202. doi:10.1038/onc.2012.599
• 34 Chacon R, Tossen G, Loria FS. et al. CASE 2. Response in a patient with metastatic adrenal cortical carcinoma with thalidomide. J Clin Oncol 2005; 23: 1579-1580
• 35 Dixit K, Shablak A, Jacob K. et al. Thalidomide therapy for metastatic adrenal carcinoma. Endocrine Abstracts 2008; 15: P155
• 36 Fassnacht M, Johanssen S, Quinkler M. et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: Proposal for a Revised TNM Classification. Cancer 2009; 115: 243-250
• 37 Weiss LM, Medeiros LJ, Vickery Jr. AL. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol 1989; 13: 202-206
• 38 Beuschlein F, Weigel J, Saeger W. et al. Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection. J Clin Endocrinol Metab 2015; 100: 841-849 doi:10.1210/jc.2014-3182
• 39 Libe R, Borget I, Ronchi CL. et al. Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): An European Network for the Study of Adrenal Tumor (ENSAT) study. Ann Oncol 2015; 26: 2119-2125 doi:10.1093/annonc/mdv329
• 40 Eisenhauer EA, Therasse P, Bogaerts J. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European journal of cancer (Oxford, England : 1990) 2009; 45: 228-247 doi:10.1016/j.ejca.2008.10.026
• 41 Kroiss M, Reuss M, K?hner D. et al. Sunitinib inhibits cell proliferation and alters steroidogenesis by down-regulation of HSD3B2 in adrenocortical carcinoma cells. Frontiers in Endocrinology 2011; 2
• 42 Mariniello B, Rosato A, Zuccolotto G. et al. Combination of sorafenib and everolimus impacts therapeutically on adrenocortical tumor models. Endocr Relat Cancer 2012; 19: 527-539 doi:ERC-11-0337 [pii] 10.1530/ERC-11-0337
• 43 van Erp NP, Guchelaar HJ, Ploeger BA. et al. Mitotane has a strong and a durable inducing effect on CYP3A4 activity. Eur J Endocrinol 2011; 164: 621-626 doi:EJE-10-0956 [pii] 10.1530/EJE-10-0956
• 44 Kroiss M, Quinkler M, Lutz WK. et al. Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. Clin Endocrinol (Oxf) 2011; 75: 585-591 doi:10.1111/j.1365-2265.2011.04214.x
• 45 Teo SK, Colburn WA, Tracewell WG. et al. Clinical pharmacokinetics of thalidomide. Clinical pharmacokinetics 2004; 43: 311-327 doi:10.2165/00003088-200443050-00004
• 46 Naing A, Lorusso P, Fu S. et al. Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. Br J Cancer 2013; 108: 826-830 doi:bjc201346 [pii] 10.1038/bjc.2013.46
• 47 Ganesan P, Piha-Paul S, Naing A. et al. Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer. Investigational new drugs 2013; 31: 1505-1513 doi:10.1007/s10637-013-0013-1
• 48 Kulke MH, Stuart K, Enzinger PC. et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006; 24: 401-406
• 49 Shao YY, Lin ZZ, Hsu C. et al. Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma. Oncology 2012; 82: 59-66 doi:10.1159/000336126